血液系统恶性肿瘤患者的新型冠状病毒肺炎结局
The outcome of COVID-19 in patients with hematological malignancy.
作者信息
Tığlıoğlu Pınar, Albayrak Murat, Tığlıoğlu Mesut, Öztürk Hacer Berna Afacan, Aras Merih Reis, Sağlam Buğra, Maral Senem
机构信息
Diskapi Yildirim Beyazit Training and Research Hospital, Department of Hematology, University of Health Sciences, Ankara, Turkey.
出版信息
Memo. 2022;15(1):83-89. doi: 10.1007/s12254-021-00775-5. Epub 2021 Dec 9.
OBJECTIVE
The aim of this study was to examine the effect of coronavirus disease 2019 (COVID-19) on the malignancy-related clinical course and overall survival, and to determine the factors affecting mortality.
METHODS
This retrospective study included 77 patients with hematological cancer and COVID-19. Patients were sub-grouped for analysis as survivors and non-survivors.
RESULTS
COVID-19 was seen more frequently in myeloproliferative neoplasms (MPN), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) patients. Mortality rate due to COVID-19 was 20.8%. No statistically significant difference was determined between the survivor and non-survivor groups with respect to age and gender, presence of any comorbidity, leukocyte, neutrophil, lymphocyte, and monocyte values. Platelet count and hemoglobin count were significantly lower in the group with mortality than in the group with recovery.
CONCLUSION
It should be kept in mind that low hemoglobin and platelet levels contribute to mortality. In addition, it is important to protect patients with hematological cancer from COVID-19 and undertake effective vaccination due to its mortal course.
目的
本研究旨在探讨2019冠状病毒病（COVID-19）对恶性肿瘤相关临床病程及总生存期的影响，并确定影响死亡率的因素。
方法
这项回顾性研究纳入了77例血液系统癌症合并COVID-19的患者。将患者分为生存者和非生存者亚组进行分析。
结果
COVID-19在骨髓增殖性肿瘤（MPN）、非霍奇金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者中更为常见。COVID-19导致的死亡率为20.8%。在年龄、性别、是否存在任何合并症、白细胞、中性粒细胞、淋巴细胞和单核细胞值方面，生存者和非生存者组之间未发现统计学上的显著差异。死亡组的血小板计数和血红蛋白计数明显低于恢复组。
结论
应牢记低血红蛋白和血小板水平会导致死亡。此外，由于其致命病程，保护血液系统癌症患者免受COVID-19感染并进行有效疫苗接种非常重要。
Zotero 插件